Navigation Links
Medivation Reports Third Quarter 2008 Financial Results and Provides Corporate Update
Date:11/10/2008

seases and offer hope to critically ill patients and their caregivers. The Company's current clinical development program includes a pivotal and confirmatory Phase 3 trial of Dimebon in Alzheimer's disease and a Phase 1-2 clinical trial of MDV3100 in patients with castration-resistant (also known as hormone-refractory) prostate cancer. Medivation recently announced that it plans to continue further development of Dimebon in patients with mild-to-moderate Huntington's disease based on the positive results seen in its Phase 2 trial. In September 2008, Medivation entered into a global agreement with Pfizer Inc to develop and commercialize Dimebon for the treatment of Alzheimer's and Huntington's diseases. For more information, please visit us at http://www.medivation.com.

This press release contains forward-looking statements, including statements regarding future clinical development plans and milestones, which are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Any statements contained in this press release that are not statements of historical fact may be deemed to be forward-looking statements. Forward-looking statements involve risks and uncertainties that could cause Medivation's actual results to differ significantly from those projected, including, without limitation, risks related to progress, timing and results of Medivation's clinical trials, difficulties or delays in obtaining regulatory approval, enrollment of patients in Medivation's clinical trials, partnering of Medivation's product candidates, manufacturing of Medivation's product candidates, competition with Medivation's product candidates should they receive marketing approval, the adequacy of Medivation's financial resources, unanticipated expenditures or liabilities, intellectual property matters, and other risks detailed in Medivation's filings with the Securities and Exchange Commissi
'/>"/>

SOURCE Medivation, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related biology technology :

1. Medivation Announces Third Quarter 2008 Teleconference and Webcast on November 10, 2008
2. Medivation Announces Expiration of Hart-Scott-Rodino Waiting Period for Collaboration With Pfizer
3. Medivation Announces Presentation of 24-Week Clinical Data of MDV3100 in Castration-Resistant Prostate Cancer Patients
4. Medivation Receives Corporate Achievement Award From Huntingtons Disease Society of America
5. Medivation to Host Conference Call at 8:30 a.m. Eastern Time Tomorrow to Discuss Partnering Plans for Dimebon
6. Medivation Announces Participation in Upcoming Conferences
7. Medivation Reports Second Quarter 2008 Financial Results and Provides Corporate Update
8. Medivation Announces Second Quarter 2008 Teleconference and Webcast on August 11, 2008
9. Medivation Announces Presentation at the BMO Capital Markets 2008 Focus on Healthcare Conference on August 5
10. Medivation Announces Presentation of Positive MDV3100 Clinical Data in Castration-Resistant Prostate Cancer Patients
11. Medivation Announces Senior Management Promotions
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... PA (PRWEB) January 15, 2014 The Pittcon ... publisher of Food Safety Tech , an e-Journal and ... signed an agreement for the second year for the co-location ... Pittcon 2014. The partnership provides that the registration fee to ...
(Date:1/15/2014)... MINNEAPOLIS , Jan. 15, 2014 ­ RedBrick ... and behavior change technology, today announces that EmblemHealth ... insurer and wellness company, is now providing the RedBrick ... digital coaching program, to all of its members. EmblemHealth ...
(Date:1/15/2014)... Rochester, NY (PRWEB) January 15, 2014 The ... cause a major disease. One of these latent viruses is ... is rheumatoid arthritis (RA). Rheumatoid arthritis (RA) is a chronic ... the theory, a study found that RA patients have high ...
(Date:1/15/2014)... 15, 2014 TaiGen Biotechnology Company, Limited ("TaiGen") today ... R-Pharm, a leading Russian pharmaceutical company, to develop and ... Russian Federation , Turkey ... is a novel antibiotic for the treatment of bacterial ...
Breaking Biology Technology:Pittcon Announces Second Year Partnership With Food Safety Tech 2Pittcon Announces Second Year Partnership With Food Safety Tech 3EmblemHealth Selects RedBrick Health to Power its Next-Generation Health Engagement and Behavior Change System 2EmblemHealth Selects RedBrick Health to Power its Next-Generation Health Engagement and Behavior Change System 3Study: Rheumatoid Arthritis (RA) Patients Have EBV; The CBCD Says this is Consistent with Microcompetition 2Study: Rheumatoid Arthritis (RA) Patients Have EBV; The CBCD Says this is Consistent with Microcompetition 3TaiGen Biotechnology Signed Exclusive License Agreement with R-Pharm for Nemonoxacin (Taigexyn(R)) 2TaiGen Biotechnology Signed Exclusive License Agreement with R-Pharm for Nemonoxacin (Taigexyn(R)) 3TaiGen Biotechnology Signed Exclusive License Agreement with R-Pharm for Nemonoxacin (Taigexyn(R)) 4
... -- Spectrum Equity Investors of Boston will become the ... national provider of technology to mortgage lenders. , , ... an $84 million recapitalization of Mortgagebot. , ,Following the ... join Mortgagebot's board of directors. Terms of the transaction ...
... -- Metavante Corp., the financial technology subsidiary of Marshall ... of Nashville, Tenn., The company will continue to operate ... subsidiary of Metavante , with existing management continuing ... the transaction were not disclosed. , ,LINK2GOV provides ...
... The WiCell Research Institute's announcement Monday that it has ... to create the nation's first National Stem Cell Bank ... and innovative approach to the new field of research. ... opposition to embryonic stem cell research, the path forward ...
Cached Biology Technology:Boston equity firm becomes majority owner of Cedarburg-based Mortgagebot 2Metavante acquiring LINK2Gov 2WiCell to host new national stem cell bank 2WiCell to host new national stem cell bank 3WiCell to host new national stem cell bank 4
(Date:7/9/2014)... considered a healthy source of protein, that,s not why the ... be presented at Tops Club Inc.,s annual International Recognition Days ... are 20-something women who want dishes that are quick, easy ... "They basically seem to care less about any health benefits ... it to look good and because it,s quick to cook ...
(Date:7/9/2014)... , an associate professor of plant pathology and ... been awarded the 2014 Alexopoulos Prize by ... to advancing the science of mycology the study ... yeasts, lichens, plant pathogens, and medically important fungi. , ... outstanding early-career mycologist. Stajich received the award last month ...
(Date:7/9/2014)... 2014) Emerging fungal pathogens pose a greater ... causing population declines of amphibians, bats, corals, bees ... South Florida published in the prestigious journal ... or immunological resistance to a deadly chytrid fungus ... "Acquired resistance is important because it is the ...
Breaking Biology News(10 mins):UC Riverside plant pathologist receives national recognition 2USF study: Amphibians can acquire resistance to deadly fungus 2
... AWRE ), a leading supplier of broadband technology and biometrics ... 30, 2010.   Revenues for the third quarter of ... million in the same quarter last year. Net income for the ... These results compared to a net loss of $1.1 million, or ...
... BOSTON The discovery that a protein called Rictor plays ... AKT oncogene could provide scientists with a new molecular target ... September 2010 issue of the journal Molecular Cell , ... Medical Center (BIDMC). The oncogenic cousin, known as ...
... Nanomedicine Center for Nucleoprotein Machines has received an award ... its renewal by the National Institutes of Health (NIH). ... of a clinically viable gene correction technology for single-gene ... disease. Sickle cell disease is a genetic condition ...
Cached Biology News:Aware, Inc. Reports Third Quarter 2010 Financial Results 2Aware, Inc. Reports Third Quarter 2010 Financial Results 3Aware, Inc. Reports Third Quarter 2010 Financial Results 4Aware, Inc. Reports Third Quarter 2010 Financial Results 5Rictor protein offers scientists a new molecular target for cancer therapies 2NIH renews Nanomedicine Center focused on treating single-gene disorders for $16.1 million 2NIH renews Nanomedicine Center focused on treating single-gene disorders for $16.1 million 3NIH renews Nanomedicine Center focused on treating single-gene disorders for $16.1 million 4
... 14 3C protease from human rhinovirus (HRV ... Novagen brand line of restriction grade proteases. ... recombinant 6XHis-fusion protein, which recognizes the same ... The small, 22 KDa size of the ...
...
... a tradition of progressive centrifuge design and ... The Centra-CL3 and Centra-CL3R (refrigerated) general purpose ... Quality Control Over Sample Preparation , ... up to 99 protocols and has speed ...
PP2B-Abeta (C-20)...
Biology Products: